| Market Cap | 7.86M |
| Revenue (ttm) | 1.73M |
| Net Income (ttm) | -10.89M |
| Shares Out | 8.93M |
| EPS (ttm) | -1.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,196 |
| Open | 0.8900 |
| Previous Close | 0.9100 |
| Day's Range | 0.8704 - 0.9010 |
| 52-Week Range | 0.5500 - 3.0600 |
| Beta | 1.30 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | May 15, 2025 |
About POAI
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid wa... [Read more]
Financial Performance
In 2024, Predictive Oncology's revenue was $1.62 million, a decrease of -0.24% compared to the previous year's $1.63 million. Losses were -$12.66 million, -9.44% less than in 2023.
Financial StatementsNews
Court Denies Renovaro Motion for an Expedited Trial in July
PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, In...
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples Company Leverages More Than Twenty Years of Drug Response Data Derived from Massi...
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"
Latest developments expand Predictive's AI-driven drug discovery platform to include biomarker discovery and drug repurposing
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensiv...
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extens...
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Deal positions STREAMWAY ® Systems with an established market leader to drive accelerating growth
Predictive Oncology Closes Registered Direct Offering
PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its pre...
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing
Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types
Certis Oncology Announces Issuance of U.S. Patent for Its Proprietary CertisAI Predictive Oncology Intelligence™ Platform
SAN DIEGO--(BUSINESS WIRE)-- #CertisAI--Certis Oncology Solutions, a precision oncology and translational science company, announced today that the United States Patent and Trademark Office (USPTO) ha...
AIRNA Appoints Matthew Hawryluk as Chief Business Officer
CAMBRIDGE, Mass. & TÜBINGEN, Germany--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the...
Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay
Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe...
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncol...
Predictive Oncology Announces Agreement to be Acquired by Renovaro
- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications –
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value Company initiates process to explore a broad range of strategic alternatives to maximize shar...
Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host inve...
Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript
Predictive Oncology Inc. (NASDAQ:POAI) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Glenn Garmont – Investor Relations Raymond Vennare – Chairman and Chief Executi...
Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update
Company to host investor call and webcast today, August 14th, at 8:30am EDT Company to host investor call and webcast today, August 14th, at 8:30am EDT
Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, ex...
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreeme...
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Predictive Oncology's organ-specific in vitro models are designed to better mimic the physiological environment of human tissue
Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
Presentation to highlight Company's novel application of AI/machine learning capabilities utilizing its proprietary biobank of more than 150,000 tumor samples to guide leading biopharma partners throu...
Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Study successfully demonstrated Predictive's ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone Study suc...